Bio-Techne Completes Acquisition of Asuragen, Inc.
MINNEAPOLIS, April 6, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced it has completed the acquisition of Asuragen, Inc. The transaction included initial consideration of $215 million in cash plus contingent consideration of up to $105 million upon the achievement of certain future milestones. The Asuragen acquisition adds a leading portfolio of best-in-class molecular... Read more